Ningbo MedicalSystem Biotechnology Co Ltd Asset Resilience Ratio
Ningbo MedicalSystem Biotechnology Co Ltd asset resilience ratio. Ningbo MedicalSystem Biotechnology Co Ltd (300439) has an Asset Resilience Ratio of 7.27% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Ningbo MedicalSystem Biotechnology Co Lt fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Ningbo MedicalSystem Biotechnology Co Ltd (2015–2024)
Asset resilience ratio of Ningbo MedicalSystem Biotechnology Co Ltd from 2015 to 2024. This chart shows how Ningbo MedicalSystem Biotechnology Co Ltd's Asset Resilience Ratio has changed over time. Read Ningbo MedicalSystem Biotechnology Co Lt (300439) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Ningbo MedicalSystem Biotechnology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Ningbo MedicalSystem Biotechnology Co Lt total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥265.90 Million | 7.27% |
| Total Liquid Assets | CN¥265.90 Million | 7.27% |
Asset Resilience Insights
- Limited Liquidity: Ningbo MedicalSystem Biotechnology Co Ltd maintains only 7.27% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Ningbo MedicalSystem Biotechnology Co Ltd Industry Peers by Asset Resilience Ratio
Compare Ningbo MedicalSystem Biotechnology Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Lonza Group AG
SW:LONN |
Diagnostics & Research | 3.04% |
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
Dr. Lal Path Labs Ltd.
NSE:LALPATHLAB |
Diagnostics & Research | 13.43% |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882 |
Diagnostics & Research | 0.14% |
|
Cowealth Medical China Co.Ltd.
SHG:603122 |
Diagnostics & Research | 2.25% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Prodia Widyahusada Tbk PT
JK:PRDA |
Diagnostics & Research | 7.82% |
|
Scope Fluidics SA
WAR:SCP |
Diagnostics & Research | 16.51% |
Ningbo MedicalSystem Biotechnology Co Ltd Asset Resilience Ratio by Year (2015–2024)
Ningbo MedicalSystem Biotechnology Co Ltd asset resilience ratio by year from 2015 to 2024. The table below shows the annual Asset Resilience Ratio data for Ningbo MedicalSystem Biotechnology Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.35% | CN¥161.08 Million ≈ $23.57 Million |
CN¥3.71 Billion ≈ $542.17 Million |
+4.18pp |
| 2023-12-31 | 0.17% | CN¥6.00 Million ≈ $877.99K |
CN¥3.49 Billion ≈ $510.58 Million |
-2.06pp |
| 2022-12-31 | 2.24% | CN¥80.17 Million ≈ $11.73 Million |
CN¥3.58 Billion ≈ $524.40 Million |
-0.57pp |
| 2021-12-31 | 2.80% | CN¥100.70 Million ≈ $14.74 Million |
CN¥3.59 Billion ≈ $525.80 Million |
-2.87pp |
| 2017-12-31 | 5.67% | CN¥242.70 Million ≈ $35.51 Million |
CN¥4.28 Billion ≈ $626.09 Million |
-4.27pp |
| 2016-12-31 | 9.95% | CN¥340.00 Million ≈ $49.75 Million |
CN¥3.42 Billion ≈ $500.20 Million |
-10.10pp |
| 2015-12-31 | 20.04% | CN¥290.00 Million ≈ $42.44 Million |
CN¥1.45 Billion ≈ $211.71 Million |
-- |
About Ningbo MedicalSystem Biotechnology Co Ltd
Medicalsystem Biotechnology Co., Ltd. engages in the research, development, production, and sales of in vitro diagnostic products in China. It is also involved in the provision of Three-party medical diagnosis services. The company offers automated chemistry analyzers; and automated chemiluminescence immunoassay analyzer; hematology analyzers and reagents; total laboratory automation system; mass… Read more